Intimation of the approval of the Board of Directors for the Appointment of Cost Auditor for the Financial Year 2025-26
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Novartis India, at its meeting on July 29, 2025, approved the appointment of M/s. D.C. Dave & Co. (Firm Registration Number: 000611), a firm of Practicing Cost Accountants, as the Cost Auditor of the company for FY 2025-26, effective April 1, 2025. D.C. Dave & Co. is described as a leading firm experienced in cost audit, compliance, assurance, and consulting services. The remuneration for the Cost Auditor will be placed before shareholders for approval via a Postal Ballot. The intimation was filed under SEBI Listing Regulations, signed by Company Secretary Chandni Maru.
This is a routine regulatory compliance filing required under SEBI rules for companies in cost-intensive sectors. There is no material impact on shareholders or the stock price, and it does not involve any change in financial auditors, directors, or senior management.